Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates
WAKIX®(pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020 Clinical Utility of WAKIX was...
WAKIX®(pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020 Clinical Utility of WAKIX was...
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on...
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at...
VANCOUVER, British Columbia, March 25, 2021 (GLOBE NEWSWIRE) -- PureK Holdings Corp. (the "Company" or "PureK") (TSX Venture: PKAN) is...
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing...
Refreshed board to bring fresh perspectives, relevant expertise and diverse experienceNEW YORK and CLEVELAND, March 25, 2021 (GLOBE NEWSWIRE) --...
TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" or the "Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a...
TORONTO, March 25, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical...
Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for...
CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
PARIS, March 25, 2021 (GLOBE NEWSWIRE) -- ORPEA SA Pre Stabilisation Notice HSBC (contact: 'synd manager'; telephone: +44 207 992...
233% increase in Q/Q cannabis net revenue$4.3 million positive adjusted EBITDA in Q4 202042% and 501% increase in Q/Q medical...
Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5 Announced strategic collaboration...
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results Breakthrough Therapy Designation granted by the FDA for tebentafusp...
Conference Call and Webcast at 8:30 a.m. EDT Today Continued progress in OVAL Phase 3 registration enabling study investigating VB-111...
Sanford Health partners with Congenica to provide answers for undiagnosed rare disease patients Multi-year study will use Congenica’s platform for...
PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative...
-AGTC’s deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience...
-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model -- Preclinical data demonstrates the...
LA JOLLA, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- MatriSys Bioscience, a company harnessing beneficial bacteria to treat inflammatory skin...